Systemic treatment in patients with Child–Pugh B liver dysfunction and advanced hepatocellular carcinoma

Autor:	Frederico Costa, Bertram Wiedenmann, Christoph Roderburg, Raphael Mohr, Ghassan K. Abou‐Alfa
Jazyk:	angličtina
Rok vydání:	2023
Předmět:	Child–Pugh B cirrhosis hepatocellular carcinoma immuno‐oncology multi‐kinase inhibitors Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Zdroj:	Cancer Medicine, Vol 12, Iss 13, Pp 13978-13990 (2023)
Druh dokumentu:	article
ISSN:	2045-7634
DOI:	10.1002/cam4.6033
Popis:	Abstract Hepatocellular carcinoma (HCC) is a major cause of death among patients with liver cirrhosis. The rise of immuno‐oncology has revolutionized treatment for advanced HCC. However, most pivotal randomized controlled trials have excluded patients with moderate liver dysfunction (Child–Pugh–Turcotte B), despite the high incidence of liver disease in patients with HCC at the time of diagnosis. Overall survival in patients with HCC and moderate liver dysfunction treated with sorafenib has been found to be only approximately 3–5 months, underlining the need for improved treatment algorithms for this increasingly important subgroup of patients. In this review, we summarize available data on the treatment of patients with HCC and moderate liver dysfunction. Opportunities, as well as clinical challenges, are discussed in detail, highlighting potential changes to the therapeutic landscape.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/747696b1fb5b4f988dbf26409b98fa8a Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.